Literature DB >> 16696686

FK506, a secondary metabolite produced by Streptomyces, presents a novel antiviral activity against Orthopoxvirus infection in cell culture.

S A Reis1, N Moussatché, C R A Damaso.   

Abstract

AIMS: To investigate the antiviral potential of the macrolide FK506, produced by Streptomyces tsukubaensis, against Orthopoxvirus infection in cell culture, and determine the replicative stage of viral cycle affected by the treatment. METHODS AND
RESULTS: Cell lines were infected with different Orthopoxviruses and treated with FK506. The macrolide inhibited the replication of the prototypic Orthopoxvirus, vaccinia virus strain WR, with an IC50 of 12.05 micromol l(-1). Progeny production of other Orthopoxviruses was also inhibited by FK506 at noncytotoxic concentrations, as evaluated by the neutral-red uptake assay and metabolic labelling of cellular proteins. By Western blot assay, we detected a severe inhibition (approximately 87.6% +/- 2.78%) of VV strain WR post-replicative protein synthesis. A similar reduction of virus DNA accumulation, as observed by slot-blot assay, probably accounts for the subsequent inhibition of virus late proteins.
CONCLUSIONS: The macrolide FK506, isolated from S. tsukubaensis, presents a novel anti-poxvirus activity, probably targeting the stage of DNA replication during Orthopoxvirus infection. SIGNIFICANCE AND IMPACT OF THE STUDY: The secondary metabolite FK506, isolated from the culture filtrate of S. tsukubaensis, shows a pleiotropic range of activities, and might be a valuable tool as a lead structure in the generation of non-immunosuppressant analogues with strong anti-poxvirus activity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16696686     DOI: 10.1111/j.1365-2672.2006.02855.x

Source DB:  PubMed          Journal:  J Appl Microbiol        ISSN: 1364-5072            Impact factor:   3.772


  6 in total

1.  Bioactive compounds from marine actinomycetes.

Authors:  Renu Solanki; Monisha Khanna; Rup Lal
Journal:  Indian J Microbiol       Date:  2009-01-08       Impact factor: 2.461

2.  Replication of human coronaviruses SARS-CoV, HCoV-NL63 and HCoV-229E is inhibited by the drug FK506.

Authors:  Javier Carbajo-Lozoya; Marcel A Müller; Stephan Kallies; Volker Thiel; Christian Drosten; Albrecht von Brunn
Journal:  Virus Res       Date:  2012-02-10       Impact factor: 3.303

Review 3.  Virus-host interactomes--antiviral drug discovery.

Authors:  Yue Ma-Lauer; Jian Lei; Rolf Hilgenfeld; Albrecht von Brunn
Journal:  Curr Opin Virol       Date:  2012-10       Impact factor: 7.090

Review 4.  Emerging paradigms of viral diseases and paramount role of natural resources as antiviral agents.

Authors:  R Sagaya Jansi; Ameer Khusro; Paul Agastian; Ahmed Alfarhan; Naif Abdullah Al-Dhabi; Mariadhas Valan Arasu; Rajakrishnan Rajagopal; Damia Barcelo; Amal Al-Tamimi
Journal:  Sci Total Environ       Date:  2020-11-07       Impact factor: 7.963

5.  Streptomyces tsukubensis VKM Aс-2618D-an Effective Producer of Tacrolimus.

Authors:  V Yu Poshekhontseva; V V Fokina; S V Tarlachkov; A V Machulin; A A Shutov; M V Donova
Journal:  Appl Biochem Microbiol       Date:  2021-12-14       Impact factor: 0.886

Review 6.  Unraveling Nutritional Regulation of Tacrolimus Biosynthesis in Streptomyces tsukubaensis through omic Approaches.

Authors:  María Ordóñez-Robles; Fernando Santos-Beneit; Juan F Martín
Journal:  Antibiotics (Basel)       Date:  2018-05-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.